AstraZeneca PLC is a company within the Healthcare category. AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company. It focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals (including Cardiovascular, Renal, Metabolism, Respiratory, and Immunology).
AstraZeneca PLC was founded in 1999 (via merger); Astra founded 1913, Zeneca demerged from ICI in 1993. and is headquartered in Cambridge, UK.
AstraZeneca PLC is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for AstraZeneca PLC is Strong. Significant factual deltas detected.
AI models classify AstraZeneca PLC as a Challenger. AI names competitors first.
AstraZeneca PLC appeared in 7 of 8 sampled buyer-intent queries (88%). AstraZeneca dominates pharmaceutical and oncology-related queries but faces high competition in broader 'lifestyle' health queries from consumer-facing health sites like Mayo Clinic or WebMD.
AstraZeneca is perceived as a top-tier global pharmaceutical leader with deep roots in British and Swedish industry. AI models accurately categorize its therapeutic focus and historical mergers, though they may over-index on its COVID-19 vaccine history compared to its current growth drivers in oncology and rare disease. Key gap: The shift in focus away from the COVID-19 vaccine toward specialized oncology and rare diseases (via the Alexion acquisition) may lag in general summaries.
Of 6 key facts verified about AstraZeneca PLC, 5 are well-documented (likely accurate across AI models), 1 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
Ambiguity regarding the current status and production of the COVID-19 vaccine (Vaxzevria) following its withdrawal from several markets in 2024.
Buyers turn to AstraZeneca PLC for Public Health Initiatives: Governments and organizations investing in preventative health and sanitation without pharmaceutical intervention., In-house Drug Development: Contract Research Organizations (CROs) developing proprietary internal generic formulations for local markets., among 2 documented problem areas.
Buyers evaluating AstraZeneca PLC typically ask AI models about "top oncology drug manufacturers", "who makes Tagrisso and Farxiga", "biotech companies in Cambridge UK", and 4 similar queries.
AstraZeneca PLC's main competitors are Pfizer Inc. According to AI models, these are the brands most frequently named alongside AstraZeneca PLC in buyer-intent queries.
AI models suggest Alternative Treatment Modalities as alternatives to AstraZeneca PLC, typically when buyers ask for lower-cost, simpler, or more specialized options.
AstraZeneca PLC's core products are Oncology therapies (Tagrisso, Imfinzi, Lynparza), BioPharmaceuticals (Farxiga, Brilinta), Rare Disease (Soliris, Ultomiris), and Respiratory (Symbicort, Fasenra)..
AstraZeneca PLC uses Enterprise/Custom (Pharmaceutical pricing via health systems/insurers).
AstraZeneca PLC serves Healthcare systems, hospitals, pharmacies, and patients globally across 125+ countries..
AstraZeneca PLC AstraZeneca distinguishes itself through its industry-leading oncology pipeline and its strategic 'Biology-First' approach to drug discovery across diverse therapeutic areas.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/astrazeneca-plc
Last analyzed: April 10, 2026
Founded: 1999 (Merger)
Headquarters: Cambridge, United Kingdom